SIGMA-ALDRICH sigma-aldrich.com Material Safety Data Sheet
1. PRODUCT AND COMPANY IDENTIFICATION
Sigma-Aldrich 3050 Spruce Street SAINT LOUIS MO 63103 USA
2. HAZARDS IDENTIFICATION Emergency Overview OSHA Hazards Target Organ Effect, Harmful by ingestion., Teratogen Target Organs GHS Label elements, including precautionary statements
Do not eat, drink or smoke when using this product.
IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
Dispose of contents/container to an approved waste disposal plant.
HMIS Classification Health hazard: Chronic Health Hazard: Flammability: Physical hazards: NFPA Rating Health hazard: Reactivity Hazard: Potential Health Effects Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
May be harmful if absorbed through skin. May cause skin irritation.
Ingestion
Sigma - S8260
3. COMPOSITION/INFORMATION ON INGREDIENTS
α-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-α,α′-diol Albuterol
Salbutamol 18559-94-9 242-424-0
4. FIRST AID MEASURES General advice Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. If inhaled If breathed in, move person into fresh air. If not breathing give artificial respiration Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
5. FIRE-FIGHTING MEASURES Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special protective equipment for fire-fighters Wear self contained breathing apparatus for fire fighting if necessary.
6. ACCIDENTAL RELEASE MEASURES Personal precautions Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation. Environmental precautions Do not let product enter drains. Methods and materials for containment and cleaning up Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.
7. HANDLING AND STORAGE Precautions for safe handling Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection. Conditions for safe storage Keep container tightly closed in a dry and well-ventilated place.
Sigma - S8260 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Contains no substances with occupational exposure limit values.
Personal protective equipment Respiratory protection Where risk assessment shows air-purifying respirators are appropriate use a dust mask type N95 (US) or type P1 (EN 143) respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Hand protection Handle with gloves. Eye protection Safety glasses with side-shields conforming to EN166 Skin and body protection Choose body protection according to the amount and concentration of the dangerous substance at the work place. Hygiene measures Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.
9. PHYSICAL AND CHEMICAL PROPERTIES Appearance Safety data
10. STABILITY AND REACTIVITY Chemical stability Stable under recommended storage conditions. Conditions to avoid no data available Materials to avoid Strong oxidizing agents Hazardous decomposition products Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx)
11. TOXICOLOGICAL INFORMATION Acute toxicity LD50 Oral - rat - 660 mg/kg Skin corrosion/irritation no data available Serious eye damage/eye irritation
Sigma - S8260 Respiratory or skin sensitization no data available Germ cell mutagenicity
no data available Carcinogenicity
No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.
Reproductive toxicity May cause congenital malformation in the fetus.
Reproductive toxicity - mouse - Subcutaneous Effects on Newborn: Biochemical and metabolic.
Reproductive toxicity - Human - female - Oral Maternal Effects: Uterus, cervix, vagina.
Developmental Toxicity - rat - Intravenous Effects on Embryo or Fetus: Other effects to embryo.
Specific target organ toxicity - single exposure (GHS) no data available Specific target organ toxicity - repeated exposure (GHS) no data available Aspiration hazard no data available Potential health effects Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion
May be harmful if absorbed through skin. May cause skin irritation.
Signs and Symptoms of Exposure Tremors, Palpitation, Headache, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Additional Information RTECS: ZE4400000
12. ECOLOGICAL INFORMATION Toxicity Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil
Sigma - S8260 PBT and vPvB assessment no data available Other adverse effects
13. DISPOSAL CONSIDERATIONS Product Observe all federal, state, and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Contaminated packaging Dispose of as unused product.
14. TRANSPORT INFORMATION DOT (US) Not dangerous goods IMDG Not dangerous goods IATA Not dangerous goods
15. REGULATORY INFORMATION OSHA Hazards Target Organ Effect, Harmful by ingestion., Teratogen DSL Status All components of this product are on the Canadian DSL list. SARA 302 Components SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. SARA 313 Components SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313. SARA 311/312 Hazards Acute Health Hazard, Chronic Health Hazard Massachusetts Right To Know Components No components are subject to the Massachusetts Right to Know Act. Pennsylvania Right To Know Components New Jersey Right To Know Components California Prop. 65 Components This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.
16. OTHER INFORMATION Further information Copyright 2010 Sigma-Aldrich Co. License granted to make unlimited paper copies for internal use only.
Sigma - S8260
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Co., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.
Sigma - S8260
Erfahrungen mit dem DECT-Telefon Als ich im Herbst 2004 begann, an Zeichen eines „Überlastungssyndroms“ zu leiden (Erschöpfungszustände, Durchfälle, dazu anfallsweise auftretende Blutdruckkrisen), war für meine Umgebung klar, dass diese mit meiner Lebenssituation zusammen- hängen. „Das ist der Stress“, „Setz’ dich mal aufs Sofa und leg’ die Beine hoch!“ oder „Machen
Bruno S., Vierling G.M., Esteban R. et al.; Efficacy and Safety of Boceprevir plus Peginterferon-Ribavirin in Patients with HCV G1 Infection and Advanced Fibrosis/Cirrhosis1 SPRINT-2: disegno dello studio2 Metodi : studio di superiorità di fase 3, multicentrico, internazionale, randomizzato, in doppio cieco, controllato con placebo, condotto su 1097 soggetti adulti affetti da